Cabaletta Bio Inc. (CABA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
XMEX 
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with strong EULAR 2026 data and a compelling $2.90/share entry point. CABA's rese-cel is advancing across five indications, with pivotal myositis and systemic sclerosis trials, clean safety profile, and automated manufacturing via Cellares. Recent $150M raise with participation from Eli Lilly and top biotech funds strengthens CABA's financial runway and strategic optionality, supporting a 2H27 BLA timeline.
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cabaletta Bio: Do You Buy With The Insiders?
Cabaletta Bio continues to advance its engineered cell therapy pipeline targeting autoimmune diseases, maintaining cautious optimism. Recent insider share purchases have apparently bolstered confidence in CABA's prospects following key data releases since October. At Q3 2025, CABA reported $60.2 million in cash and $99.7 million in short-term investments, supporting ongoing development.
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
Here is how Cabaletta Bio, Inc. (CABA) and Celcuity, Inc. (CELC) have performed compared to their sector so far this year.
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cabaletta Bio: Still Optimistic, With News Being Guided To Be Shared Soon
Cabaletta Bio (CABA) offers pioneering CAR T-cell therapy for autoimmune diseases, with recent data showing promising efficacy and manageable safety. CABA's lead candidate, rese-cel, has demonstrated meaningful responses in lupus and scleroderma, with additional pivotal data and FDA discussions expected in 2025-2027. Despite a recent stock rally and a strong pipeline, CABA faces significant cash runway concerns, making future dilution likely before regulatory milestones.
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Cabaletta Bio: Finding Optimism In Dire Straits
Cabaletta Bio, Inc.'s CD19-directed CAR T-cell therapy shows early promise in treating autoimmune diseases, despite limited patient numbers and follow-up time. Financially, Cabaletta Bio has enough cash to operate for 5–6 quarters, assuming no further expense growth or additional financing. Risks include the aggressive nature of CAR T-cell therapy for non-life-threatening diseases and competition from other cell therapy approaches.
